We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Instrument-Light CRISPR-Based POC Tests to Rapidly and Accurately Detect Pathogens and Genetic Markers

By LabMedica International staff writers
Posted on 29 Aug 2023

New generation point-of-care (POC) CRISPR-based tests capable of detecting pathogens and genetic markers could revolutionize diagnosis and accessibility to testing for clinics, hospitals, and resource-limited areas. More...

CrisprBits (Bengaluru, India), a biotech start-up specializing in CRISPR gene-editing technology, and MolBio Diagnostics (Goa, India), a pioneer in POC diagnostic solutions, have entered into a strategic collaboration to revolutionize POC diagnostics by integrating CRISPR technology into POC tests. The collaboration will leverage CrisprBits' biotechnology expertise and MolBio's capabilities in translation, manufacturing, and distribution to create POC tests that can detect pathogens and genetic markers. These tests will be accessible in clinics, hospitals, and regions with limited resources.

This strategic partnership is expected to advance accessible, cost-effective, and accurate diagnostic testing at the forefront of healthcare. Utilizing the remarkable sensitivity and specificity of RNA guide-based target identification of nucleic acids, along with the unique cis and trans-cleavage properties of certain Cas enzymes, CrisprBits has developed a platform known as PathCrisp. This platform is designed to create rapid, accurate, and affordable POC tests for a diverse range of diseases and health conditions. While CrisprBits will lead the development of the PathCrisp platform for POC testing, MolBio will leverage its extensive manufacturing capacity and well-established sales and marketing network to promote and distribute these innovative POC tests worldwide.

"The reimagination of health systems in India has to ride on a central role played by “pervasive” diagnostic tests POCTs (Point-of-care tests) that are light on instruments, affordable, and designed for ease of use by community health workers. This would enable better preventive care and early detection interventions in treatment,” said Dr. Vijay Chandru, Chief Scientific Officer and Co-founder, CrisprBits. “This innovation has to be driven in the LMICs (Low and Middle Income Countries) as developed economies have legacy infrastructure that addresses these issues with access to labs or clinics at a different scale. By teaming up with Molbio Diagnostics, we are combining our innovations in instrument-light CRISPR POCTs to develop and distribute a new generation of tests that are pervasive and will enable early detection and timely treatment."

"We are very excited about this partnership with CrisprBits. The coming together of their innovation and Molbio’s strengths in translation, manufacturing, and distribution has the potential to rapidly provide cutting-edge diagnostics solutions where it is required the most,” added Dr. Chandrashekar Nair, Chief Technical Officer of Molbio Diagnostics. “This collaboration aligns perfectly with our overarching mission to provide reliable and accessible point-of-care diagnostic solutions that empower healthcare professionals globally."

Related Links:
CrisprBits 
MolBio Diagnostics 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
8-Channel Pipette
SAPPHIRE 20–300 µL
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.